GPR30 has also been involved in estrogenic signaling in malignant cells, such as breast cancer and endometrial cancer [20, 21], suggesting that GPR30 may act at the crossroads between cancer cells and these important components of the tumor microenvironment. Here, GPER1 is linked to breast carcinoma.